CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA

SHANGHAI, March 1, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for...

from PR Newswire: https://ift.tt/2NBQwJy